West raises full-year sales and adjusted EPS guidance after third quarter
West Pharmaceutical Services raised its full-year net sales and adjusted-diluted EPS guidance alongside its third-quarter 2026 results. The higher outlook sets up the company’s next earnings update as the test of whether stronger expectations are translating into sustained operating performance.
PR NEWSWIRE / FILEThe story
West Pharmaceutical Services announced its third-quarter 2026 results on Oct. 29 and raised its guidance for full-year net sales and adjusted-diluted EPS. The company said the update in Exton, Pennsylvania, without further figures in the announcement available here.
West’s prior full-year 2025 figures included $3.1B in revenue and $6.79 in diluted EPS, with gross and net margins of 35.9% and 16.1%, respectively. Those are the older annual results and provide the operating baseline for the revised 2026 outlook.
The announcement concerns West’s injectable-solutions and services business, whose products connect the company to pharmaceutical manufacturers and other healthcare customers. The concrete mechanism for the raised outlook is the company’s expectation for higher full-year sales and adjusted-diluted EPS.
The size of the guidance increase, the quarter’s detailed sales and profit figures, and the factors behind the revision remain open questions. The next quarterly results should show whether the revised outlook is being supported by reported performance rather than guidance alone.
The next key evidence is West’s fourth-quarter and full-year 2026 results, including full-year sales, adjusted-diluted EPS and the company’s initial 2027 outlook.
Our read · Thu, Oct 29
West (WST) raised full-year net sales and adjusted-diluted EPS guidance after reporting third-quarter 2026 results.
Why. Higher full-year sales and adjusted-diluted EPS guidance improves the near-term operating setup, while the company’s older FY2025 baseline shows $3.1B of revenue and $6.79 in diluted EPS. The next quarter must translate the revised outlook into reported sales and earnings; without the size of the increase or current-period figures, the strength of the read remains limited.
Both cases
What could change this view: The setup fails if fourth-quarter results do not support the raised full-year outlook or if the next outlook weakens.
Who reported it · 1
Keep reading
Latest on the Wire
Taiwan readies $15BN fund as Seoul waives margin calls after AI selloffSMCI files 10-Q — Quarterly Report: 10-QHims ends GLP-1 compounding in Lilly deal as shares rallyUS adds 165,000 jobs in October as wages rise and unemployment fallsTrump weighs renewed Iran strikes as negotiators review a new proposalContinue on the Wire →Latest on the Wire
Trump weighs renewed Iran strikes as negotiators review a new proposalBitcoin holds $76,000 as Nasdaq futures rebound 1.5% before jobs dataFed holds rates as stable labor market keeps December hike on trackTesla to wind down Cybertruck production as Musk pivots to roboticsContinue on the Wire →Top this week
Democrats sweep Congress, setting Trump up for legislative gridlockFutures rebound after blue sweep as dollar slides and gold tops $4,000Bitcoin plunges as AI chip selling drags Nasdaq down more than 2%Trump’s Republican Party faces a midterm verdict from US voters todayBitcoin faces renewed pressure as Binance hack intensifies market fearAbout this report
Reported by PR Newswire as West Reports Third-Quarter 2026 Results
, . Who answers for this
The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →